Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Akcea Therapeutics Inc (NQ: AKCA )

18.17 USD UNCHANGED
Last Price Updated: 5:44 PM EDT, Oct 9, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Akcea Therapeutics Inc

< Previous 1 2 3 4 5 Next >
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary, Akcea Therapeutics, received the Prix Galien USA Award for the Best Biotechnology Product in 2020 in recognition of TEGSEDI,... 
From PR Newswire
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics
Transaction creates a stronger, more efficient company 
From PR Newswire
IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Investigations; Investors are Encouraged to Contact the Firm - AKCA, BLDR, DCOM, STND
Halper Sadeh LLP, a global investor rights law firm, is investigating: 
From PR Newswire
SHAREHOLDER ALERT: WeissLaw LLP Reminds AKCA, IMMU, and MXIM Shareholders About Its Ongoing Investigations
From PR Newswire
Lifshitz Law Firm, P.C. Announces Investigation of Akcea Therapeutics, Inc. (NASDAQ: AKCA), BMC Stock Holdings, Inc. (NASDAQ: BMCH), Builders FirstSource, Inc. (NASDAQ: BLDR), Cancer Genetics, Inc. (N
From PR Newswire
IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Is Investigating the Following Companies; Shareholders are Encouraged to Contact the Firm – CGIX, BYFC, BMCH, AKCA
From ACCESSWIRE
Moore Kuehn Encourages RST, AKCA, DCOM, and SBPH Investors to Contact Law Firm
Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to... 
From PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Reminds Investors About Its Ongoing Investigations; Shareholders are Encouraged to Contact the Firm – CBMG, AKCA, VRTU, IMMU
From ACCESSWIRE
Lifshitz Law Firm, P.C. Announces Investigation of Aimmune Therapeutics, Inc., (NASDAQ:AIMT), Akcea Therapeutics, Inc., (NASDAQ:AKCA), BMC Stock Holdings, Inc., (NASDAQ:BMCH), and Cancer Genetics, Inc
From GlobeNewswire News Releases
ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders are Encouraged to Contact the Firm – AIMT, AKCA, PTI
From ACCESSWIRE
INVESTIGATION ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm – RST, CBMG, AIMT, AKCA
Halper Sadeh LLP, a global investor rights law firm, is investigating: 
From Business Wire News Releases
SHAREHOLDER ALERT: WeissLaw LLP Reminds AKCA and AIMT Shareholders About Its Ongoing Investigations
From PR Newswire
Lifshitz Law Firm, P.C. Announces Investigation of Aimmune Therapeutics, Inc., Akcea Therapeutics, Inc., BMC Stock Holdings, Inc., Builders FirstSource, Inc., Broadway Financial Corporation, Cancer G
From PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm - PRNB, BLDR, AKCA, YIN
Halper Sadeh LLP, a global investor rights law firm, is investigating: 
From PR Newswire
Kaskela Law LLC Announces Stockholder Investigation of Akcea Therapeutics, Inc. (AKCA) and Encourages Investors to Contact the Firm
Kaskela Law LLC announces that it is investigating Akcea Therapeutics, Inc. ("Akcea") (NASDAQ: AKCA) on behalf of the company's shareholders. 
From PR Newswire
AKCEA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akcea Therapeutics, Inc. - AKCA
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akcea Therapeutics, Inc. (NasdaqGS: AKCA) to... 
From Business Wire News Releases
Stocks Trading Above 20Days Moving Average: $VRA $JNCE $AKCA
Tags The Market Signal
From The Market Signal
INVESTOR ALERT: Monteverde & Associates PC Announces an Investigation of Akcea Therapeutics, Inc. - AKCA
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Akcea Therapeutics,... 
From PR Newswire
(AKCA) Alert: Johnson Fistel Investigates Proposed Sale of Akcea Therapeutics; Is $18.15 a Fair Price?
Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Akcea Therapeutics, Inc. (NASDAQ: AKCA) ("Akcea" or the "Company") breached their... 
From PR Newswire
SHAREHOLDER ALERT: WeissLaw LLP Investigates Akcea Therapeutics, Inc.
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Akcea Therapeutics, Inc. ("AKCA" or the "Company") (NASDAQ: AKCA) in... 
From PR Newswire
AKCEA THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of AKCA and Encourages Investors to Contact the Firm
From GlobeNewswire News Releases
Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics
- Ionis to acquire remaining 24% of common stock of Akcea it does not already own for $18.15 per share in cash 
From PR Newswire
Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020
Results from Phase 2 study demonstrate patients receiving vupanorsen experienced significant, dose-dependent reductions in triglyceride levels, ANGPTL3 and additional lipid parameters compared to... 
From PR Newswire
Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020
Results in late-breaking presentation show patients with hypertriglyceridemia experienced dose-dependent reductions in triglyceride levels, apoC-III, and significant reductions in atherogenic... 
From PR Newswire
Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020
Late-breaking presentation to focus on efficacy and safety data of vupanorsen in patients with hypertriglyceridemia, type 2 diabetes and non-alcoholic fatty liver disease 
From PR Newswire
Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020
Data presentation will highlight efficacy, safety and tolerability of investigational medicine in patients with hypertriglyceridemia and cardiovascular disease 
From PR Newswire
Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany
WAYLIVRA is the only treatment option for patients with familial chylomicronemia syndrome, or FCS, in Europe 
From PR Newswire
Akcea Reports Financial Results and Highlights for Second Quarter 2020
Global Net Product Revenues of $16 Million, an Increase of 66% Year-Over-Year 
From PR Newswire
Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Austria for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
TEGSEDI is the first antisense oligonucleotide medicine available to hATTR patients with polyneuropathy in Austria for at-home subcutaneous injection 
From PR Newswire
Akcea Therapeutics to Hold Second Quarter 2020 Financial Results Webcast
Webcast scheduled for Tuesday, August 4 at 4:30 p.m. Eastern Time 
From PR Newswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
X